8098622

Source:http://linkedlifedata.com/resource/pubmed/id/8098622

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0005532, umls-concept:C0008972, umls-concept:C0023473, umls-concept:C0026764, umls-concept:C0038250, umls-concept:C0040736, umls-concept:C0229601, umls-concept:C0260206, umls-concept:C0278488, umls-concept:C0314603, umls-concept:C0680532, umls-concept:C1514926, umls-concept:C1517499, umls-concept:C1861886, umls-concept:C2603343
pubmed:issue	2
pubmed:dateCreated	1993-6-24
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/9008950
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Etoposide, http://linkedlifedata.com/resource/pubmed/chemical/Ifosfamide, http://linkedlifedata.com/resource/pubmed/chemical/Melphalan
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1043-0342
pubmed:author	pubmed-author:Cottler-FoxMM, pubmed-author:CowanKK, pubmed-author:DunbarC ECE, pubmed-author:GoodmanSS, pubmed-author:LeitmanSS, pubmed-author:NienhuisA WAW, pubmed-author:O'ShaughnessyJJ, pubmed-author:QuesenberryPP, pubmed-author:SorrentinoB PBP, pubmed-author:StewartF MFM
pubmed:issnType	Print
pubmed:volume	4
pubmed:owner	NLM
pubmed:authorsComplete	N
pubmed:pagination	205-22
pubmed:dateRevised	2007-11-15
pubmed:meshHeading	pubmed-meshheading:8098622-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:8098622-Bone Marrow, pubmed-meshheading:8098622-Bone Marrow Transplantation, pubmed-meshheading:8098622-Breast Neoplasms, pubmed-meshheading:8098622-Cisplatin, pubmed-meshheading:8098622-Clinical Protocols, pubmed-meshheading:8098622-Combined Modality Therapy, pubmed-meshheading:8098622-Cyclophosphamide, pubmed-meshheading:8098622-Etoposide, pubmed-meshheading:8098622-Feasibility Studies, pubmed-meshheading:8098622-Gene Therapy, pubmed-meshheading:8098622-Genetic Vectors, pubmed-meshheading:8098622-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:8098622-Humans, pubmed-meshheading:8098622-Ifosfamide, pubmed-meshheading:8098622-Leukemia, Myelogenous, Chronic, BCR-ABL Positive, pubmed-meshheading:8098622-Melphalan, pubmed-meshheading:8098622-Multiple Myeloma, pubmed-meshheading:8098622-Neoplasm Metastasis, pubmed-meshheading:8098622-Retroviridae, pubmed-meshheading:8098622-Transfection, pubmed-meshheading:8098622-Transplantation, Autologous, pubmed-meshheading:8098622-Whole-Body Irradiation
pubmed:year	1993
pubmed:articleTitle	Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't